3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
4
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Conditions
Uterine Cervical Neoplasms
2
Endometrial Neoplasms
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Dysplasia
1
Rectal Neoplasms
1
Papillomavirus Infections
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Cystadenocarcinoma, Serous
1
Carcinoma in Situ
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
33
Paclitaxel
27
Cyclophosphamide
25
Carboplatin
23
olaparib
21
Fulvestrant
15
fludarabine
14
Trastuzumab
14
aldesleukin
13
Docetaxel
13
Early Intervention, Educational
12
Surveys and Questionnaires
11
veliparib
10
palbociclib
10
Methods
10
Gemcitabine
10
Blood Specimen Collection
10
Nivolumab
9
Flow Cytometry
9
Biopsy
9
Bevacizumab
9
sargramostim
8
niraparib
7
liposomal doxorubicin
7
Therapeutics
7
Taxes
7
Standard of Care
7
Psychiatric Rehabilitation
7
Magnetic Resonance Spectroscopy
7
talazoparib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Diphenhydramine
×
Gynecologic
×
Clear all
NCT04237090
2020-10-12
PREMED-F1
Ciusss de L'Est de l'Île de Montréal
Phase 3
Completed
27 enrolled